Buying a deficit? The pharmaceutical company announced its withdrawal from medical services

[pharmaceutical network industry trends] recently, humanwell announced that humanwell Zhongxiang Medical Management Co., Ltd., a wholly-owned subsidiary of the company, intends to sell the real estate, decoration and other real estate in the new hospital area of the people's Hospital of Zhongxiang City held by it, and the total sale price will be determined according to the audit results of the final accounts of the project Humanwell said in the announcement that after preliminary calculation, the investment income of the project is about 40 million yuan The author understands that in March 2014, humanwell announced that the company would arrange about 20 hospitals in the next 3-5 years, and take different M & A methods according to different types of hospitals; in 2015, humanwell had about 5 actions to arrange hospitals In the 2015 financial report, humanwell pharmaceutical mentioned that the company actively layout the medical service field and build a regional medical service group, which helps to further extend the downstream industry chain However, since 2018, humanwell has successively sold its shares in Huangshi Daye non ferrous Hospital Management Co., Ltd and other relevant hospitals, and gradually withdrawn from the medical service field This move has attracted the attention of the industry From the perspective of the reasons behind, some insiders believe that the company's development in the field of medical services is not optimistic, which makes the performance under pressure, or the reason why humanwell pharmaceutical exits the field of medical services By selling hospital related assets, humanwell medicine may be able to return to its main business and focus on development According to the third quarter report disclosed by humanwell, the company's net profit in the first three quarters increased nearly 15% year on year In the first three quarters, the company achieved revenue of 16.104 billion yuan, an increase of 18.95% year on year; net profit attributable to shareholders of the listed company was 746 million yuan, an increase of 14.99% year on year; net profit attributable to shareholders of the listed company after deducting non recurring profit and loss was 507 million yuan, an increase of 26.76% year on year; basic earnings per share was 0.51 yuan In fact, in recent years, it is not uncommon for listed pharmaceutical companies to purchase hospitals through "buy buy" and lay out the medical service field However, the hospital is a long-term investment, and there are also risks in the layout of pharmaceutical enterprises in this field I have been in "listed pharmaceutical companies want to buy hospitals, but also need calm objective analysis!"! 》Three reasons are mentioned in the article First, the medical industry belongs to the heavy asset industry, and the capital construction and large-scale medical equipment in the operation of the hospital need a lot of capital investment to support the operation; second, the hospital has a strong regional character, many hospitals are serving the local people, so after being acquired, it is difficult to significantly improve the operating income in the short term; third, most of the listed pharmaceutical enterprises invest Our hospitals are all general hospitals, so it needs a lot of investment and a long payback period to rebuild the brand Therefore, the acquisition of listed pharmaceutical companies needs calm and objective analysis Of course, there are more than Renfu pharmaceutical companies selling hospitals It is understood that since 2018, many enterprises, including China Resources 39, Yibai pharmaceutical, Jingfeng pharmaceutical and so on, have begun to spin off the hospital business; in December 2018, Jingfeng pharmaceutical issued a notice to transfer 100% equity of its wholly-owned subsidiary Chengdu Jinsha hospital Co., Ltd at a price of 150 million yuan; in addition, on January 17, 2019, Xianju pharmaceutical issued a notice that because of the oral medical service industry Inconsistent with the long-term development strategic direction of the company, it is proposed to transfer all the equity of the subsidiary in the hospital According to Xianju pharmaceutical, the long-term development strategy of the oral medical service industry is inconsistent with that of the company The transfer is to optimize the asset structure, further integrate resources and focus on the main business Industry insiders remind that the acquisition of hospitals by listed pharmaceutical companies also needs objective and calm analysis Generally, the acquisition investment of hospitals needs a lot of capital investment, which is easy to disperse the energy of the main industry of pharmaceutical companies, and may "lose more than gain" In general, at present, the exploration of domestic pharmaceutical companies in the field of medical treatment has gradually become calm.